Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Benzer Materyaller

• Clinical development of nintedanib for advanced non-small-cell lung cancer
  Yazar:: Takeda, Masayuki, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
  Yazar:: Akashi, Y, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
  Yazar:: Takeda, Masayuki, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors in patients with epidermal growth factor receptor gene mutation-positive lung cancer
  Yazar:: Takeda, Masayuki, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
  Yazar:: Okamoto, Isamu, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)